Acquired Neuromyotonia

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Acquired Neuromyotonia is not the name you expected.

Disorder Subdivisions

  • None

General Discussion

Acquired neuromyotonia is an inflammatory disorder characterized by abnormal nerve impulses from the peripheral nerves that result in continuous muscle fiber activity. Affected individuals often experience progressive muscle stiffness and cramping especially in the hands and feet, increased sweating, and delayed muscle relaxation. Symptoms may persist even during sleep or under general anesthesia.


Acquired neuromyotonia is characterized by involuntary continuous muscle fiber activity (fasciculations) that cause stiffness and delayed relaxation in the affected muscles. Muscle twitching with a rippling appearance (myokymia) may occur along with these symptoms. Affected individuals may, at times, be unable to coordinate voluntary muscle movement and find difficulty in walking (ataxia). Other symptoms may include staggering and reeling (titubation), stiffness, and lack of balance in response to being startled. There may be diminished spontaneous gross motor activity.

The disorder is characterized by progressive stiffness, cramping, and weakness. Muscle activity is constant, and patients describe the feeling of continuous writhing or rippling of muscles under the skin. These movements continue during sleep. Diminished reflexes are also frequently a sign of this disorder. In some instances, muscle relaxation following voluntary muscle movement is delayed (grip myotonia) in the affected muscles. For example, affected individuals may be not be able to open their fists or eyes immediately after closing them tightly for a few seconds.

Affected individuals frequently have excessive sweating (hyperhidrosis), rapid heartbeats (tachycardia) and weight loss.

In slightly fewer than 20% of the cases, a set of symptoms, including arrhythmias, excessive salivation, memory loss, confusion, hallucinations, constipation, personality change and/or sleep disorders, are found. In such cases the disorder may be referred to as Morvan syndrome.

Approximately 20% of affected individuals have a tumor of the thymus gland (thymoma). The thymus glands are the source of a number of specialized cells associated with autoimmune functions. The disorder is also associated with peripheral neuropathies and autoimmune diseases including myasthenia gravis in some individuals. It has also been reported following infections and radiation therapy.


Acquired neuromyotonia is an autoimmune disease in which the immune system malfunctions so that it damages parts of one's own body. Approximately 40% of affected individuals have antibodies to voltage-gated potassium channels (VGKC's) that affect the points at which the signals from the nerve fiber meet the muscle cell (neuromuscular junction).

Affected Populations

Aquired neuromyotonia is a rare disorder affecting males and females but is slightly more common among men. Disease onset is usually between the ages of 15 and 60 years but has also been reported in childhood.


The diagnosis of acquired neuromyotonia is based on the presence of continuous muscle contractions (myokymia), especially in the face and hands, rhythmic tics or twitches (fasciculations), and muscle cramps. The diagnosis is confirmed by studies of the electrical signs of muscle activity (electromyography).

Standard Therapies


Acquired neuromyotonia may be treated with anticonvulsant drugs such as phenytoin or carbamazepine, which may stop the abnormal impulses and prevent the symptoms from reoccurring. Plasma exchange (plasmapheresis) and intravenous immune globulin have been effective in a few cases but no long-term, controlled, clinical studies have been carried out.

Testing for acetylcholine receptor antibodies should be done if thymoma is suspected. The thymus gland should be surgically removed if thymoma is present.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Vincent A. Neuromyotonia. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:635.

Beers MH, Berkow R, eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1496.

Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. W.B. Saunders Co., Philadelphia, PA; 1996:2170.

Adams RD, Victor M, Ropper AA, eds. Principles of Neurology. 6th ed. McGraw-Hill Companies. New York, NY; 1997:1490-93.


Arimura K, Sonoda Y, Watanabe O, et al. Isaac's syndrome as a potassium channelopathy of the nerve. Muscle Nerve. 2002;Supple 11:S55-58.

Gutmann L, Libell D, Gutmann L. When is myokymia neuromyotonia? Muscle Nerve. 2001;24:151-53.

Benetar M. Neurological potassium channelopathies. QJM. 2000;93:787-97.

Vincent A. Understanding myotonia. Muscle Nerve. 2000;23:655-57.

Lawson K. Is there a role for potassium channel openers in neuronal ion channel disorders? Expert Opin Invest Drugs.2000;9:2269-80


Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. The Lancet. 2011;377:942-955.

Gonzelez G, Barros G, Russi ME, Nunez A and Scavone C. Acquired neuromyotonia in childhood: case report and review. Ped Neurol. 2008:38;61-63.

Imam I, Edwards, S and Hanemann CO. Acquired neuromyotonia following upper respiratory tract infection: a case report. Cases Journal. 2009:2:7982.

Vucic S, Cheah BC, Yiannikas C, Vincent A and Kiernan M. Corticomotoneuonal function and hyperexcitability in acquired neuromyotonia. Brain. 2010:133;2727-2733.

Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26:702-07.

Daube JR. Myokymia and neuromyotonia. Muscle Nerve. 2001;24:1711-12.

Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to votage-gated potassium channels. Brain. 2001;124:2417-26.

Hayat GR, Kulkantrakorn K, Campbell WW, et al. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci. 2000;181:38-43.

Nakatsuji Y, Kaido M, Sugai F, et al. Isaacs' syndrome successfully treated by a immunoadsorption plasmapheresis. Acta Neurol Scand. 2000;102:271-73.

Alessi G, De Reuck J, De Bleecker, et al. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg. 2000;102:173-75.

Van den Berg JS, van Engelen BG, Boerman RH, et al. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous immunoglobulin. J Neurol. 1999;57:623-25.


NINDS Isaac's syndrome Information Page. Last Updated February 8, 2013. Accessed Jan 22, 2014.

D'Adamo MC, Hanna MG, Di Giovanni G, et al. Episodic Ataxia Type 1. 2010 Feb 9 [Updated 2012 Aug 16]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: // Accessed Jan 22, 2014.

Supporting Organizations

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126
Gaithersburg, MD 20898-8126
Tel: (301)251-4925
Fax: (301)251-4911
Tel: (888)205-2311
Website: //

NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801
Bethesda, MD 20824
Tel: (301)496-5751
Fax: (301)402-2186
Tel: (800)352-9424
Website: //

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see